456 results on '"Campbell, Matthew T"'
Search Results
52. Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
53. Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).
54. A phase 2 study of the combination dostarlimab with niraparib in patients with penile carcinoma that has progressed following chemotherapy.
55. Outcomes with sacituzumab govitecan (SG) in patients (pts) with advanced urothelial carcinoma (aUC) and variant histologies (VH): Analysis of the UNITE study.
56. Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.
57. Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.
58. Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract: The MD Anderson Cancer Center (MDACC) experience.
59. Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database.
60. Clinical efficacy of lurbinectedin in metastatic neuroendocrine carcinomas of the genitourinary tract: Multi-institutional real-world experience.
61. Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
62. Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.
63. Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN+PEM).
64. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival
65. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma
66. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
67. Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
68. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors
69. Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study
70. Special Issue Editorial: Emerging Therapies in Renal Cell Carcinoma: The Road to a Cure?
71. Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
72. Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).
73. A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
74. Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001).
75. A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).
76. Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma
77. Variables Affecting the Internal Energy of Peptide Ions During Separation by Differential Ion Mobility Spectrometry
78. Identifying the D-Pentoses Using Water Adduction to Lithium Cationized Molecule
79. Increased Ion Transmission for Differential Ion Mobility Combined with Mass Spectrometry by Implementation of a Flared Inlet Capillary
80. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer
81. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship
82. Malignant Tumors of the Adrenal Gland
83. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
84. A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140).
85. A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer.
86. A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140).
87. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
88. 464: Outcomes After Radiotherapy for Locally Advanced and Node Positive Muscle Invasive Bladder Cancer
89. Arterially Delivered Mesenchymal Stem Cells Prevent Obstruction-Induced Renal Fibrosis
90. Toll-Like Receptor 4: A Novel Signaling Pathway During Renal Fibrogenesis
91. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications
92. Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience.
93. Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.
94. Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC).
95. Mixed methods assessment of providers’ needs in the management of advanced renal cell carcinoma.
96. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC).
97. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience
98. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
99. Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder
100. First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.